IRCT20200105046010N27尚未招募未知
In- Vivo Bioequivalence study of Rivaroxaban tablet 10 and 20mg Jaber-ebne Hayyan Pharma with brand drug (XARELTO® 10 and 20mg Bayer, Germany) in Iranian healthy volunteers.
Jaber Ibn Hayyan Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index(18-28)
- •Informed consent
- •Age(18-60)
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
招募中
不适用
Bioequivalence study of Rivaroxaban 20 mg tabletBioequivalence study of Rivaroxaban 20 mg tablet (Tehran Darou) versus Xalerto® 20 mg (Bayer) Tablet after single oral dosing in healthy volunteers.IRCT20220111053692N4tehran darou Pharmaceutical Company24
尚未招募
不适用
A bioequivalence study of Rivaroxaban 20 mg tab compared to Xarelto 20 mg tab manufactured by Bayer in 24 healthy volunteers under fasting conditioIRCT20220209053979N1Pars Darou24
尚未招募
Unknown
Bioequivalence study of Rivaroxaban 20mg tabletIRCT20200623047902N28Darou Darman Arang company24
已完成
1 期
Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male SubjectsEmbolism, Atrial Fibrillation and Venous ThrombosisNCT02537405Bayer40
招募中
3 期
the effect of rivaroxaban on the prevention of deep vein thrombosis in nephrotic syndromephrotic syndrom.Nephrotic syndromeIRCT20220422054617N1Shiraz University of Medical Sciences20